Tocagen Announces Closing of IPO and Exercise of the Underwriters’ Option

USC Stevens Center for Innovation is pleased to share the news of our licensee, Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, which on April 13th, 2017 announced the pricing of its initial public offering of 8,500,000 shares of common stock at a public offering price of $10.00 per share. Tocagen is developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer.

To read the full press release, visits the Tocagen website.

–published May 8, 2017